Literature DB >> 31631714

Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges.

Aleksandra Berkan-Kawińska1, Anna Piekarska1.   

Abstract

Background and Aims: Hepatocellular carcinoma (HCC) is the most common primary liver cancer. The etiology of this disease is known in 90% of the patients, and it is viral in most of the cases. According to recent predictions, nearly half of the world population will be suffering from obesity by 2030. Consequently, non-alcoholic fatty liver disease (NAFLD) may play a growing role in HCC epidemiology. In this review, we sought to explore the relationship between liver steatosis and HCC.
Methods: A narrative review was conducted using the PubMed MeSH search. The eligible papers were identified using a standard PubMed search with relevant key terms and various synonyms.
Results: According to the results, patients with NAFLD-HCC tended to be older than those with hepatitis C virus (HCV)-HCC, and they were more often obese and had concomitant diseases, such as diabetes. On the other hand, the synthetic liver function was better preserved in NAFLD-HCC patients, who also obtained lower scores on the Model for End-stage Liver Disease (MELD) and Child-Turcotte-Pugh (CTP). However, it has to be noted that HCC in patients with non-alcoholic steatohepatitis (NASH) may develop without underlying cirrhosis. Although NASH-HCC is usually smaller and well-differentiated compared to HCV-HCC, the prognosis is similar in both groups. Efficient HCC screening in NASH cirrhosis poses a challenge because it is difficult to perform ultrasound examination in obese patients and alfa-fetoprotein level is no longer considered reliable.Conclusions: The constantly increasing prevalence of NAFLD in the general population can contribute to a growing role of NAFLD/NASH in HCC epidemiology. Moreover, some particular challenges specific for patients with liver steatosis may impede proper HCC diagnosis, treatment and follow-up.

Entities:  

Keywords:  Hepatocellular carcinoma; liver cirrhosis; non-alcohol steatohepatitis; non-alcoholic fatty liver disease

Year:  2019        PMID: 31631714     DOI: 10.1080/03007995.2019.1683817

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  8 in total

1.  Response differences of HepG2 and Primary Mouse Hepatocytes to morphological changes in electrospun PCL scaffolds.

Authors:  Thomas S R Bate; Victoria L Gadd; Stuart J Forbes; Anthony Callanan
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

2.  Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.

Authors:  Haoran Yang; Qingmei Deng; Tun Ni; Yu Liu; Li Lu; Haiming Dai; Hongzhi Wang; Wulin Yang
Journal:  Int J Biol Sci       Date:  2021-10-11       Impact factor: 6.580

Review 3.  Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models.

Authors:  Wojciech Andrzej Straś; Dariusz Wasiak; Beata Łągiewska; Olga Tronina; Marta Hreńczuk; Joanna Gotlib; Wojciech Lisik; Piotr Małkowski
Journal:  Ann Transplant       Date:  2022-01-26       Impact factor: 1.530

4.  Gender disparity and temporal trend of liver cancer in China from 1990 to 2019 and predictions in a 25-year period.

Authors:  Tingting Yue; Ming Xu; Ting Cai; Haizhen Zhu; Mahmoud Reza Pourkarim; Erik De Clercq; Guangdi Li
Journal:  Front Public Health       Date:  2022-08-26

5.  Matrine inhibits cell growth, migration, invasion and promotes autophagy in hepatocellular carcinoma by regulation of circ_0027345/miR-345-5p/HOXD3 axis.

Authors:  Shaobing Lin; Jie Zhuang; Liping Zhu; Zongsheng Jiang
Journal:  Cancer Cell Int       Date:  2020-06-16       Impact factor: 5.722

Review 6.  Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma.

Authors:  Zobair M Younossi; Linda Henry
Journal:  JHEP Rep       Date:  2021-05-11

7.  Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019.

Authors:  Yuan Liu; Jinxin Zheng; Jialing Hao; Rang Rang Wang; Xueni Liu; Peng Gu; Hongwei Yu; Yang Yu; Chuanxing Wu; Baochi Ou; Zhihai Peng
Journal:  Cancer Med       Date:  2022-02-04       Impact factor: 4.452

Review 8.  The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.

Authors:  Qian Song; Xiang Zhang
Journal:  Biomedicines       Date:  2022-02-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.